Tag Archives: Labiotech.eu

Update: Where does Brexit leave European pharma, now that the EU has excluded the UK from drug approvals?

A European decision to exclude Britain from the EU’s drug approval system from beginning 30, 2019–the day after Brexit–has raised alarm among drugmakers, who fear the abrupt change could disrupt… Read more »

First FDA-approved gene-therapy procedure for inherited blindness performed in US. Advance is fantastic news, but same quandary: Who can afford it?

The News: Massachusetts Eye and Ear, a Harvard teaching hospital based in Boston, recently became the first institution to treat a patient’s inherited retinal disorder with gene therapy. The patient,… Read more »

Join a clinical trial? The success rate of such trials is higher than you thought, but still awfully low overall; especially for Alzheimer’s.

The News: Instead of less than 10% of drugs reaching the market, a new study has found that almost 15% of new compounds pass clinical trial–which still suggests that it’s… Read more »

Investor Alert: Qiagen grabs Spanish biotech STAT-Dx in quest for new and better diagnostic tests. My personal take.

The News: Molecular diagnostics company Qiagen NV (Hilden DEU) has agreed to acquire biotech STAT-Dx SL (Barcelona) for up to €153 million–over 3 times the total funding the Spanish company has raised… Read more »

Ablynx soars 60% on Novo’s latest hostile bid; grab a piece of this Belgian biotech because the real action’s just starting.

The News: Denmark’s Novo Nordisk A/S (Copenhagen), the world’s biggest insulin maker, went public Monday (January 8, 2018) with a €2.6-billion ($3.1 billion) bid for Belgian biotech group Ablynx NV… Read more »

French nanocap Sensorion inks deal with Aussie implant-maker Cochlear for €1.6M capital infusion, R&D collaboration. Pearl by the Mediterranean?

The News: Sensorion SA (Montpellier FRA), a tiny biotech company pioneering novel treatments for inner-ear diseases, and Cochlear Ltd. (Sydney), the global leader in implantable hearing devices, in a joint… Read more »

London-based biotech TopiVert, although invisible, intends to shake up Allergan, Shire in the huge dry-eye space.

The News: TopiVert Pharma Ltd., a clinical-stage biotechnology company developing narrow spectrum kinase inhibitors (NSKIs) for chronic inflammatory gastrointestinal (GI) and ocular diseases, has announced results from a Phase 1/2a… Read more »

Netherlands-based, emerging biotech star arGEN-X gives shareholders two doses of great news; stock skyrockets.

The News: arGEN-X SE (Breda NLD) has smoked its target of $150 million for a US stock offering, which will support its cancer and autoimmune disease antibodies through the clinical phases…. Read more »

Micro biotech Alzinova, hiding out in southwest Sweden, using proprietary peptide technology that targets key Alzheimer’s toxins.

Background: Alzinova AB (Gothenburg) is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease (AD). The company was founded in 2011… Read more »